Related Experiment Videos
Pharmacology and efficacy of vancomycin for staphylococcal infections in children
Insights
Vancomycin effectively treats serious staphylococcal infections in children. This study confirms its safety and efficacy in pediatric patients, with minimal side effects observed.
Area of Science:
- Infectious Diseases
- Pediatric Medicine
- Pharmacology
Background:
- Multiply resistant staphylococci pose a growing clinical challenge.
- Limited data exists on vancomycin use in pediatric patients.
- Staphylococcus aureus and Staphylococcus epidermidis are significant pathogens in children.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous vancomycin in pediatric patients.
- To assess vancomycin's pharmacokinetic profile in children.
- To determine vancomycin's penetration into cerebrospinal fluid in shunt infections.
Main Methods:
- Intravenous vancomycin administered to 33 pediatric patients (1 week to 16 years).
- Infections included skin/soft-tissue, osteomyelitis, pneumonia, shunt infections, endocarditis, and septicemia.
- Serum vancomycin concentrations monitored; cerebrospinal fluid penetration assessed in 10 patients.
Main Results:
- All 29 patients with proven staphylococcal infections responded to vancomycin.
- Satisfactory bacteriostatic and bactericidal titers achieved.
- Vancomycin penetration into ventricular fluid ranged from 7% to 37% (mean 18%).
- Minimal adverse events: one phlebitis, one transient AST elevation. No renal or otologic toxicity.
Conclusions:
- Vancomycin is an effective and safe treatment for staphylococcal infections in pediatric patients.
- Adequate drug dilution, slow infusion, and serum monitoring minimize side effects.
- Vancomycin demonstrates favorable efficacy and safety profile in this pediatric cohort.
Abstract:
Vancomycin is effective against most multiply resistant staphylococci, organisms that are becoming increasingly important in clinical medicine. Reported experience with vancomycin therapy in pediatric patients is limited. In this study vancomycin was administered intravenously to 33 patients whose ages ranged from one week to 16 years and who had suspected or proved infections caused by either Staphylococcus aureus or Staphylococcus epidermidis. The spectrum of staphylococcal infections included skin and soft-tissue infections and abscesses, osteomyelitis, pneumonia, shunt infections, endocarditis, and septicemia. All 29 patients with bacteriologically proved staphylococcal infections responded to vancomycin therapy. Peak and trough concentrations of vancomycin in serum produced satisfactory bacteriostatic and bactericidal titers against the infecting pathogens. In an anephric patient hemodialysis removed only negligible amounts of vancomycin. The amount of vancomycin that penetrated into ventricular fluid of 10 patients with shunt infections ranged from 7% to 37% (mean, 18%) of serum concentrations. One case of phlebitis and one case of transient elevation of serum levels of aspartate amino transferase were observed. No renal or otologic damage was detected in any patient. Adequate dilution of the drug, intravenous administration during 1 hr, and monitoring of the concentration in serum of patients undergoing long-term treatment and/or with impaired renal function minimize the likelihood of side effects. Vancomycin is an effective and safe agent for treatment of staphylococcal infections in pediatric patients.